Press Releases and Blog
Blog
Comprehensive Analysis Of PBMs From Prominent Economists Confirm Value of PBMs, Dispel FTC Findings
An important new economic analysis contradicts the findings of a recent Federal Trade Commission (FTC) interim staff report. Dennis W. Carlton, Ph.D., David McDaniel Keller
ICYMI: Experts from Competitive Enterprise Institute and Mercatus Center Highlight Fundamental Flaws in FTC PBM Suit
In case you missed it, the growing consensus surrounding the recent actions from the Federal Trade Commission (FTC), including releasing an interim staff report on
New Research Explains How PSAOs Support America’s Independent Pharmacies
What are PSAOs? Pharmacy Services Administrative Organizations, PSAOs, support America’s independent pharmacies by negotiating with PBMs on contracts for reimbursement rates and inclusion in pharmacy
The Wall Street Journal Editorial Board: “You Have To Smile At Ms. Khan Portraying Big Drug Makers As Victims In Her Suit.”
In case you missed it, The Wall Street Journal Editorial Board warns the Federal Trade Commission’s (FTC) recent enforcement action against pharmacy benefit managers (PBMs) would lead
PBMs Commit To Continued GLP-1 Coverage Options; Pharma Companies Won’t Commit To Setting Lower List Prices
The U.S. Senate Committee on Health, Education, Labor & Pensions (HELP) held a hearing, “Why Is Novo Nordisk Charging Americans with Diabetes and Obesity Outrageously High
House Judiciary Witnesses From Academia Highlight Critical Role PBMs Play
This week, the U.S. House Committee on the Judiciary Subcommittee on the Administrative State, Regulatory Reform, and Antitrust held a hearing on pharmacy benefit managers
Press Releases
Hurricane Rx Resources
PCMA is monitoring the very active hurricane season and our thoughts are with everyone affected by these storms. We hope you find the following information and
Prime Therapeutics’ Mostafa Kamal Becomes PCMA Board Chair
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is pleased to announce that Mostafa Kamal, President and Chief Executive Officer (CEO) of Prime Therapeutics
PCMA Urges HELP Committee to Pass Legislation to Increase Biosimilar Competition
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the U.S. Senate Committee on Health, Education, Labor & Pensions (HELP)
PCMA Statement on Senate HELP Committee Hearing
PBMs Are Committed to Helping Clients Navigate the GLP-1 Coverage Journey (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement ahead
PCMA Statement On FTC Enforcement Action
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the Federal Trade Commission’s (FTC) enforcement action on pharmacy benefit managers
PCMA Statement On Suit Against The FTC
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement today: “The industry trade association representing America’s pharmacy
Comprehensive Analysis Of PBMs From Prominent Economists Confirm Value of PBMs, Dispel FTC Findings
An important new economic analysis contradicts the findings of a recent Federal Trade Commission (FTC) interim staff report. Dennis W. Carlton, Ph.D., David McDaniel Keller
ICYMI: Experts from Competitive Enterprise Institute and Mercatus Center Highlight Fundamental Flaws in FTC PBM Suit
In case you missed it, the growing consensus surrounding the recent actions from the Federal Trade Commission (FTC), including releasing an interim staff report on
New Research Explains How PSAOs Support America’s Independent Pharmacies
What are PSAOs? Pharmacy Services Administrative Organizations, PSAOs, support America’s independent pharmacies by negotiating with PBMs on contracts for reimbursement rates and inclusion in pharmacy
The Wall Street Journal Editorial Board: “You Have To Smile At Ms. Khan Portraying Big Drug Makers As Victims In Her Suit.”
In case you missed it, The Wall Street Journal Editorial Board warns the Federal Trade Commission’s (FTC) recent enforcement action against pharmacy benefit managers (PBMs) would lead
PBMs Commit To Continued GLP-1 Coverage Options; Pharma Companies Won’t Commit To Setting Lower List Prices
The U.S. Senate Committee on Health, Education, Labor & Pensions (HELP) held a hearing, “Why Is Novo Nordisk Charging Americans with Diabetes and Obesity Outrageously High
House Judiciary Witnesses From Academia Highlight Critical Role PBMs Play
This week, the U.S. House Committee on the Judiciary Subcommittee on the Administrative State, Regulatory Reform, and Antitrust held a hearing on pharmacy benefit managers
ICYMI: Ryan Costello Urges Congress To Pass Patent Abuse Legislation Over Misguided Proposals Targeting PBMs
In case you missed it, Ryan Costello, former U.S. Representative (R-PA-06), urged Members of Congress to focus on solutions to stop Big Pharma’s patent abuse
ICYMI: Senate Judiciary Committee Got It Right on Big Pharma’s Patent Abuse As Root Cause Of High Rx Prices
The U.S. Senate Committee on the Judiciary held a hearing earlier this summer, “Ensuring Affordable & Accessible Medications: Examining Competition in the Prescription Drug Market.”
Reminder: Pharmacy Network Design Saves Money
Pharmacy benefit managers (PBMs) continue to work every day to lower prescription drug costs, leading to savings of an average of $1,040 per person per year. While
Recent Headlines Showcase Positive Progress Toward Cracking Down on Big Pharma’s Patent Abuse in U.S. Senate
Lawmakers’ Focus Should Remain on Anti-Competitive Drug Company Tactics that Keep Prices High, Reject Pharma-Backed Anti-PBM Agenda The U.S. Senate recently took a step
